Thomas Meyer
Chief Executive Officer
Thomas Meyer founded Auris Medical (renamed Altamira Therapeutics) in April 2003 and was the Company's sole shareholder until the end of 2007. Prior to founding Auris Medical, he was the Chief Executive Officer of Disetronic Group, a leading Swiss supplier of precision infusion and injection systems. He worked for Disetronic in various functions starting in 1988, becoming member of the Board of Directors in 1996, Deputy Chief Executive Officer in 1999 and Chief Executive Officer in early 2000. Prior to joining Disetronic, he advised several Swiss companies in strategy, marketing and corporate finance. Thomas Meyer served on the Board of Directors of several small and medium sized Swiss industrial companies; in some of them he was also a key investor. He holds a Ph.D. in business administration (Dr.rer.pol.) from the University of Fribourg, Switzerland.
Samuel A. Wickline
Chief Scientific Officer
Samuel A. Wickline, MD, is the founder of Trasir Therapeutics, Inc., which we acquired in 2021 and formed the basis for our activities in oligonucleotide delivery. Before joining Altamira Therapeutics, he was the Director of the Health Heart Institute, Chair in Cardiovascular Medicine, Professor of Cardiovascular Sciences, Molecular Physiology and Pharmacology, and Medical Engineering at the University of South Florida (USF). Previously, he was Professor of Medicine, Physics, Biomedical Engineering, and Cell Biology and Physiology at Washington University. Dr Wickline was funded continuously for 30+ years by the National Institutes of Health with research grants totaling more than $50 million. He is the author of > 300 refereed research papers and holds > 50 issued or filed U.S. patent applications.
Covadonga Pañeda
Chief Development Officer
Dr. Pañeda has over 15 years of experience in drug development. She spent 7 years as R&D Manager at Sylentis S.A., a clinical stage RNAi biopharma company and most recently, she served as Director of Development at Limm Therapeutics, a neuroimmune biopharma company. Dr. Pañeda obtained a Ph.D. in Biochemistry and Molecular Biology at the Faculty of Medicine at Universidad Autónoma, Madrid, Spain, and spent several years as a Post-doc at the Scripps Research Institute, La Jolla, CA.
Jean Lechance
OTC Consumer Health Business Unit Head
Jean Lachance joined Altamira in May 2022. He has over 20 years of experience in sales, trade marketing and marketing in the Consumer Health & OTC industries in various global, regional and local roles. In his career, Mr. Lachance led multiple brands & portfolios in the Allergy, Cough & Cold, Gastrointestinal, Nutritional & Wound care categories with companies such as Abbott, MundiPharma Consumer Care, Bayer Consumer Care & Merck Consumer Care. He holds a Bachelor Business degree from Laval University, Quebec, and an Executive Master of Business Administration (MBA) degree from UQAM University (Montreal, Canada)
Marcel Gremaud
Chief Financial Officer
Marcel Gremaud, CPA, has been Altamira Therapeutics’ Chief Financial Officer since November 2021. Mr. Gremaud has acquired more than 30 years’ experience in controlling and accounting in international pharma companies and start-ups. In 2001 he founded Gremaud GmbH, an audit and accounting company supporting companies in financial consolidation and accounting in accordance with IFRS or Swiss GAAP FER.
Thomas Meyer
Chairman of the Board, Chief Executive Officer
Thomas Meyer founded Auris Medical (renamed Altamira Therapeutics) in April 2003 and was the Company's sole shareholder until the end of 2007. Prior to founding Auris Medical, he was the Chief Executive Officer of Disetronic Group, a leading Swiss supplier of precision infusion and injection systems. He worked for Disetronic in various functions starting in 1988, becoming member of the Board of Directors in 1996, Deputy Chief Executive Officer in 1999 and Chief Executive Officer in early 2000. Prior to joining Disetronic, he advised several Swiss companies in strategy, marketing and corporate finance. Thomas Meyer served on the Board of Directors of several small and medium sized Swiss industrial companies; in some of them he was also a key investor. He holds a Ph.D. in business administration (Dr.rer.pol.) from the University of Fribourg, Switzerland.
Armando Anido
Director
Mr. Anido has been a member of our Board of Directors since April 2016. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He has served as Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc., since October 2014. Prior to Zynerba, Mr. Anido served as Chief Executive Officer of NuPathe, Inc., and Auxilium Pharmaceuticals, Inc. Prior to Auxilium, Mr. Anido held commercial leadership roles at MedImmune, Glaxo Wellcome and Lederle Labs. He is currently a member of the Board of Directors of SCYNEXIS, Inc. (SCYX), and he was a member of the Board of Directors of Aviragen Therapeutics, Inc. until it merged with Vaxart Inc. (VXRT) and Adolor Corporation until it was sold to Cubist Pharmaceuticals. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.
Mats Blom
Director
Mats Blom has been a member of our Board of Directors since April 2017. Mr. Blom is Chief Financial Officer (CFO) of NorthSea Therapeutics B.V., a biotechnology company focused on oral, structurally-engineered lipid therapeutics. Prior to joining NorthSea, he served as CFO of Modus Therapeutics A/B, a biotechnology company developing therapeutics to restore healthy blood flow for patients with debilitating diseases, Zealand Pharma A/B, a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mr. Blom has extensive managerial experience and has held CFO positions at Active Biotech AB and Anoto Group AB. Previously, he served as a management consultant at Gemini Consulting and Ernst & Young. He is currently a member of the Board of Directors of Hansa Biopharma AB (HNSA) and Pephexia Therapeutics ApS. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.
Alain Munoz
Director
Mr. Munoz, MD, has been a member of our Board of Directors since March 2018 and previously served on our Board of Directors between 2007 and 2015. Mr. Munoz is an entrepreneur and independent management consultant in the pharmaceutical and biotechnology industry. From 1990 to 2000, Dr. Munoz worked with the Fournier Group, as Research and Development Director and then Senior Vice President of the Pharmaceutical Division. He joined Fournier from Sanofi Research, where he started as Director in the cardiovascular and anti-thrombotic products department and then as Vice President international development. Dr. Munoz is qualified in cardiology and anesthesiology from the University Hospital of Montpellier, France where he was head of the clinical cardiology department. He has been a member of the Scientific Committee of the French drug agency. He serves on the Board of Zealand Pharma A/S (ZEAL.CO) Amryt Pharma Plc (AMYT.L ) and OxThera AB. He is a member of the scientific advisory board of Valneva (VLA.PA).
Margrit Schwarz
Director
Margrit Schwarz has been a member of our Board of Directors since July 2021. She is the Chief Operating Officer of Draupnir Bio, a biotechnology company in the cardiovascular space. Prior to joining Draupnir Bio, she served as Chief Scientific Officer and Head of R&D at Genevant Sciences, where she was responsible for developing a portfolio of RNAi and mRNA drug candidates in the liver and rare disease space. Previous executive and scientific leadership roles include VP & Global Head External Innovation at Roche, VP & Therapeutic Area Head Cardiorenal at Boehringer Ingelheim, and Director Research at Amgen. Dr Schwarz has led preclinical R&D and IND-enabling phases for multiple development candidates, including the anti-PCSK9 therapeutic antibody Repatha, launched in 2015. She is an Entrepreneur-in-Residence at Novo Seeds, and a contractual Expert with Innosuisse and the European Innovation Council. She has served on the Board of the KERN Conference since 2009, and as strategic advisor to life science incubators in USA and Switzerland since 2018. She holds a PhD in Biochemistry from the University of Cologne, Germany, and an MBA from Columbia University, NY.
